FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605574980> ?p ?o ?g. }

• W2605574980 endingPage "78" @default.
• W2605574980 startingPage "69" @default.
• W2605574980 abstract "Cognitive deficits represent core symptoms in schizophrenia (SZ) and predict patient outcome; however, they remain poorly treated by current antipsychotic drugs. Elevated levels of the endogenous alpha7 nicotinic receptor negative allosteric modulator and NMDA receptor antagonist, kynurenic acid (KYNA), are commonly seen in post-mortem tissue and cerebrospinal fluid of patients with SZ. When acutely or chronically elevated in rodents, KYNA produces cognitive deficits similar to those seen in the disease, making down-regulation of KYNA, via inhibition of kynurenine aminotransferase II (KAT II), a potential treatment strategy. We determined, in adult Wistar rats, if the orally available KAT II inhibitor BFF816 a) prevents KYNA elevations in prefrontal cortex (PFC) after a systemic kynurenine injection and b) reverses the kynurenine-induced attenuation of evoked prefrontal glutamate release caused by stimulation of the nucleus accumbens shell (NAcSh). Systemic injection of kynurenine (25 or 100 mg/kg, i.p.) increased KYNA levels in PFC (532% and 1104% of baseline, respectively). NMDA infusions (0.15 μg/0.5 μL) into NAcSh raised prefrontal glutamate levels more than 30-fold above baseline. The two doses of kynurenine reduced evoked glutamate release in PFC (by 43% and 94%, respectively, compared to NMDA alone). Co-administration of BFF816 (30 or 100 mg/kg, p.o.) with kynurenine (25 mg/kg, i.p.) attenuated the neosynthesis of KYNA and dose-dependently restored NMDA-stimulated glutamate release in the PFC (16% and 69%, respectively). The ability to prevent KYNA neosynthesis and to normalize evoked glutamate release in PFC justifies further development of KAT II inhibitors for the treatment of cognitive deficits in SZ." @default.
• W2605574980 created "2017-04-28" @default.
• W2605574980 creator A5000427773 @default.
• W2605574980 creator A5002953056 @default.
• W2605574980 creator A5047555416 @default.
• W2605574980 creator A5049171963 @default.
• W2605574980 date "2017-07-01" @default.
• W2605574980 modified "2023-10-16" @default.
• W2605574980 title "Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex" @default.
• W2605574980 cites W1669304804 @default.
• W2605574980 cites W1686397783 @default.
• W2605574980 cites W1955390159 @default.
• W2605574980 cites W1973320478 @default.
• W2605574980 cites W1983202833 @default.
• W2605574980 cites W1985065973 @default.
• W2605574980 cites W1985615006 @default.
• W2605574980 cites W1988983217 @default.
• W2605574980 cites W1992179353 @default.
• W2605574980 cites W1992812287 @default.
• W2605574980 cites W1993560189 @default.
• W2605574980 cites W1996580716 @default.
• W2605574980 cites W2000183088 @default.
• W2605574980 cites W2001932071 @default.
• W2605574980 cites W2004578815 @default.
• W2605574980 cites W2006875263 @default.
• W2605574980 cites W2008320953 @default.
• W2605574980 cites W2010758506 @default.
• W2605574980 cites W2013582450 @default.
• W2605574980 cites W2014887893 @default.
• W2605574980 cites W2017661386 @default.
• W2605574980 cites W2021782736 @default.
• W2605574980 cites W2028370746 @default.
• W2605574980 cites W2034000656 @default.
• W2605574980 cites W2037599428 @default.
• W2605574980 cites W2039083311 @default.
• W2605574980 cites W2039986616 @default.
• W2605574980 cites W2042847268 @default.
• W2605574980 cites W2048545238 @default.
• W2605574980 cites W2049005941 @default.
• W2605574980 cites W2059738973 @default.
• W2605574980 cites W2060050678 @default.
• W2605574980 cites W2067837882 @default.
• W2605574980 cites W2069742329 @default.
• W2605574980 cites W2076434927 @default.
• W2605574980 cites W2079199493 @default.
• W2605574980 cites W2083373623 @default.
• W2605574980 cites W2085505779 @default.
• W2605574980 cites W2089874235 @default.
• W2605574980 cites W2111909949 @default.
• W2605574980 cites W2126056252 @default.
• W2605574980 cites W2131932927 @default.
• W2605574980 cites W2142084327 @default.
• W2605574980 cites W2148945172 @default.
• W2605574980 cites W2170792659 @default.
• W2605574980 cites W2171832535 @default.
• W2605574980 cites W2201538478 @default.
• W2605574980 cites W2216398920 @default.
• W2605574980 cites W2306837648 @default.
• W2605574980 cites W2316395455 @default.
• W2605574980 cites W2345680363 @default.
• W2605574980 cites W2464310518 @default.
• W2605574980 cites W2511016742 @default.
• W2605574980 cites W2513389402 @default.
• W2605574980 cites W295621354 @default.
• W2605574980 doi "https://doi.org/10.1016/j.neuropharm.2017.04.023" @default.
• W2605574980 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5803791" @default.
• W2605574980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28419874" @default.
• W2605574980 hasPublicationYear "2017" @default.
• W2605574980 type Work @default.
• W2605574980 sameAs 2605574980 @default.
• W2605574980 citedByCount "31" @default.
• W2605574980 countsByYear W26055749802018 @default.
• W2605574980 countsByYear W26055749802019 @default.
• W2605574980 countsByYear W26055749802020 @default.
• W2605574980 countsByYear W26055749802021 @default.
• W2605574980 countsByYear W26055749802022 @default.
• W2605574980 countsByYear W26055749802023 @default.
• W2605574980 crossrefType "journal-article" @default.
• W2605574980 hasAuthorship W2605574980A5000427773 @default.
• W2605574980 hasAuthorship W2605574980A5002953056 @default.
• W2605574980 hasAuthorship W2605574980A5047555416 @default.
• W2605574980 hasAuthorship W2605574980A5049171963 @default.
• W2605574980 hasBestOaLocation W26055749802 @default.
• W2605574980 hasConcept C126322002 @default.
• W2605574980 hasConcept C134018914 @default.
• W2605574980 hasConcept C15744967 @default.
• W2605574980 hasConcept C169760540 @default.
• W2605574980 hasConcept C169900460 @default.
• W2605574980 hasConcept C170493617 @default.
• W2605574980 hasConcept C185592680 @default.
• W2605574980 hasConcept C2776038425 @default.
• W2605574980 hasConcept C2776706248 @default.
• W2605574980 hasConcept C2776841986 @default.
• W2605574980 hasConcept C2777503454 @default.
• W2605574980 hasConcept C2777896816 @default.
• W2605574980 hasConcept C2778938600 @default.
• W2605574980 hasConcept C2781195155 @default.
• W2605574980 hasConcept C515207424 @default.

• next